Xeris Biopharma Holdings, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
XERS$15.20+16.2%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of June, 2026 and December 31, 2025
Condensed Consolidated Balance Sheets
(in thousands, except share and par value)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $121,747 | $111,042 |
| Trade accounts receivable, net | 58,105 | 51,050 |
| Inventory, net | 80,930 | 68,673 |
| Prepaid expenses and other current assets | 13,975 | 9,548 |
| Total current assets | 274,757 | 240,313 |
| Property and equipment, net | 4,834 | 4,945 |
| Operating lease right-of-use assets | 21,773 | 22,112 |
| Goodwill | 22,859 | 22,859 |
| Intangible assets, net | 82,657 | 88,078 |
| Other assets | 5,025 | 5,220 |
| Total assets | $411,905 | $383,527 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $9,337 | $3,076 |
| Current portion of long-term debt | 63,783 | — |
| Current operating lease liabilities | 6,310 | 6,232 |
| Other accrued liabilities | 39,706 | 33,155 |
| Accrued trade discounts and rebates | 46,858 | 43,253 |
| Accrued returns reserve | 18,598 | 18,969 |
| Other current liabilities | 4,976 | 4,889 |
| Total current liabilities | 189,568 | 109,574 |
| Long-term debt, net of unamortized debt issuance costs | 188,807 | 220,335 |
| Non-current operating lease liabilities | 30,542 | 31,531 |
| Other liabilities | 12,722 | 8,398 |
| Total liabilities | 421,639 | 369,838 |
| Commitments and contingencies (Note 13) | ||
| Stockholders' (deficit) equity: | ||
| Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock—par value $0.0001, 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,591,637 and 166,215,410 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 18 | 17 |
| Additional paid in capital | 690,432 | 685,004 |
| Accumulated deficit | (700,174) | (671,307) |
| Accumulated other comprehensive loss | (10) | (25) |
| Total stockholders' (deficit) equity | (9,734) | 13,689 |
| Total liabilities and stockholders' equity | $411,905 | $383,527 |
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data, unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Product revenue, net | $91,004 | $67,708 | $173,458 | $125,510 |
| Royalty, contract and other revenue | 1,096 | 3,831 | 1,769 | 6,148 |
| Total revenue | 92,100 | 71,539 | 175,227 | 131,658 |
| Costs and expenses: | ||||
| Cost of goods sold | 12,512 | 11,898 | 23,086 | 20,626 |
| Research and development | 10,669 | 8,055 | 19,452 | 15,808 |
| Selling, general and administrative | 61,035 | 44,393 | 114,179 | 88,411 |
| Amortization of intangible assets | 2,711 | 2,711 | 5,421 | 5,421 |
| Total costs and expenses | 86,927 | 67,057 | 162,138 | 130,266 |
| Income from operations | 5,173 | 4,482 | 13,089 | 1,392 |
| Other income (expense): | ||||
| Interest and other income | 1,455 | 948 | 2,657 | 2,123 |
| Loss on debt extinguishment, net | (30,782) | — | (30,782) | — |
| Interest expense | (6,947) | (7,358) | (13,831) | (14,663) |
| Total other expense | (36,274) | (6,410) | (41,956) | (12,540) |
| Net loss before income taxes | (31,101) | (1,928) | (28,867) | (11,148) |
| Income tax benefit | — | — | — | — |
| Net loss | $(31,101) | $(1,928) | $(28,867) | $(11,148) |
| Other comprehensive income (loss), net of tax: | ||||
| Foreign currency translation adjustments | 14 | 1 | 15 | 1 |
| Comprehensive loss | $(31,087) | $(1,927) | $(28,852) | $(11,147) |
| Net loss per common share - basic and diluted | $(0.18) | $(0.01) | $(0.17) | $(0.07) |
| Weighted average common shares outstanding - basic and diluted | 172,823,455 | 159,459,413 | 171,679,686 | 155,972,048 |
Condensed Consolidated Statements of Stockholders' Equity (Deficit)
(in thousands, except share data, unaudited)
| Common Stock · Additional Paid InCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · TotalStockholders'Equity (Deficit) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance, December 31, 2024 | 149,429,410 | $15 | $642,256 | $(25) | $(671,861) | $(29,615) | ||
| Net loss | — | — | — | — | (9,220) | (9,220) | ||
| Exercise of stock options | 1,366,498 | — | 4,960 | — | — | 4,960 | ||
| Vesting of restricted stock units (net of 2,255,124 shares withheld for tax) | 3,721,805 | 1 | (7,999) | — | (7,998) | |||
| Issuance of common shares in partial settlement of 2025 Convertible Debt | 1,045,752 | — | 3,188 | — | — | 3,188 | ||
| Issuance of common shares in settlement of warrants | 450,585 | — | — | — | — | — | ||
| Stock-based compensation | — | — | 3,557 | — | — | 3,557 | ||
| Balance, March 31, 2025 | 156,014,050 | $16 | $645,962 | $(25) | $(681,081) | $(35,128) | ||
| Net loss | — | — | — | — | (1,928) | (1,928) | ||
| Exercise of stock options | 315,724 | — | 1,152 | — | — | 1,152 | ||
| Vesting of restricted stock units (net of 170,442 shares withheld for tax) | 680,154 | — | (859) | — | — | (859) | ||
| Issuance of common shares in settlement of 2025 Convertible Debt | 3,932,399 | — | 11,958 | — | — | 11,958 | ||
| Issuance of common stock through employee stock purchase plan | 282,435 | — | 830 | — | — | 830 | ||
| Stock-based compensation | — | — | 4,670 | — | — | 4,670 | ||
| Other comprehensive income | — | — | — | 1 | — | 1 | ||
| Balance, June 30, 2025 | 161,224,762 | $16 | $663,713 | $(24) | $(683,009) | $(19,304) | ||
| Common Stock · Additional Paid InCapital · Accumulated Other Comprehensive Loss · Accumulated Deficit · TotalStockholders'Equity (Deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance, December 31, 2025 | 166,215,410 | $17 | $685,004 | $(25) | $(671,307) | $13,689 |
| Net income | — | — | — | — | 2,234 | 2,234 |
| Exercise of stock options | 259,935 | — | 847 | — | — | 847 |
| Vesting of restricted stock units (net of 2,314,943 shares withheld for tax) | 3,808,125 | 1 | (17,018) | — | — | (17,017) |
| Issuance of common shares in settlement of warrants | 2,275,313 | — | 7,333 | — | — | 7,333 |
| Stock-based compensation | — | — | 5,924 | — | — | 5,924 |
| Other comprehensive income | — | — | — | 1 | — | 1 |
| Balance, March 31, 2026 | 172,558,783 | $18 | $682,090 | $(24) | $(669,073) | $13,011 |
| Net loss | — | — | — | — | (31,101) | (31,101) |
| Exercise of stock options | 248,124 | — | 580 | — | — | 580 |
| Vesting of restricted stock units (net of 31,690 shares withheld for tax) | 363,980 | — | (191) | — | — | (191) |
| Issuance of common stock through employee stock purchase plan | 157,592 | — | 985 | — | — | 985 |
| Issuance of common shares in settlement of warrants | 263,158 | — | 600 | — | — | 600 |
| Stock-based compensation | — | — | 6,368 | — | — | 6,368 |
| Other comprehensive income | — | — | — | 14 | — | 14 |
| Balance, June 30, 2026 | 173,591,637 | $18 | $690,432 | $(10) | $(700,174) | $(9,734) |
See accompanying notes to condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.